

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: LaPointe et al.
Serial No.: 10/043,356
Filed: January 11, 2002
For: *METHOD FOR SELECTING
MEDICAL AND BIOCHEMICAL
DIAGNOSTIC TESTS USING
NEURAL NETWORK-RELATED
APPLICATIONS*
Art Unit: 2122
Examiner: Unassigned

TRANSMITTAL LETTER

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Forms PTO-1449 (4 pages) and a cited reference for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

- [X] The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24727-0801F
Address all correspondence to:
Stephanie L. Seidman
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: LaPointe et al.
Serial No.: 10/043,356
Filed: January 11, 2002
For: *METHOD FOR SELECTING
MEDICAL AND BIOCHEMICAL
DIAGNOSTIC TESTS USING
NEURAL NETWORK-RELATED
APPLICATIONS*
Art Unit: 2122
Examiner: Unassigned

TRANSMITTAL LETTER

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202


Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Forms PTO-1449 (4 pages) and a cited reference for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 50-1213, as stated below:

- [X] The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24727-0801F
Address all correspondence to:
Stephanie L. Seidman
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant **LaPointe et al.**

Serial No.: 10/043,356

Filed: January 11, 2002

Confirmation No.: 7695

For: **METHOD FOR SELECTING
MEDICAL AND BIOCHEMICAL
DIAGNOSTIC TESTS USING
NEURAL NETWORK RELATED
APPLICATIONS**

Art Unit: 2122

Examiner: Unassigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §§ 1.97-1.98**

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Because this Supplemental Information Disclosure Statement is filed prior to receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (4 pages) and copies of the cited documents are provided herewith in connection with the above-captioned application.

U.S.S.N. 10/043,356

LaPointe et al.

INFORMATION DISCLOSURE STATEMENT

The documents listed on the Form PTO-1449 and supplied herewith are in the English language except items P, AJ, AK, AL, AM and AN, which are in the Japanese language. Item P (Japanese patent 6-119291) is provided with an English language equivalent (item AL). Items AJ, AL, AM and AN are provided with an English language equivalent (accompanying items AJ, AL, AM and AN, respectively). Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and make them of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By: 
Stephanie L. Seidman, Reg. No. 33,779

Attorney Docket No. 24727-0801F
Address all correspondence to:
Stephanie L. Seidman
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th Floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24727-801FSERIAL NO.
10/043,356LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
LaPointe *et al.*FILING DATE
June 11, 2002GROUP
2122

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	D	4	3	4	1	5	3	11/21/00	Anderson <i>et al.</i>	D24	D216	04/20/98
	B	4	8	9	4	3	2	6	01/16/90	Matsuura <i>et al.</i>	435	7	04/09/86
	C	4	9	1	9	8	8	9	04/24/90	Jones <i>et al.</i>	422	40	09/15/88
	D	5	0	3	6	4	7	9	07/30/95	Prednis <i>et al.</i>	364	580	04/20/89
	E	5	0	9	1	1	7	0	02/25/92	Navot	424	9	04/06/89
	F	5	2	7	9	9	4	1	01/18/94	Lessey	435	7.21	06/12/92
	G	5	4	7	4	9	2	7	12/12/95	Anderson <i>et al.</i>	435	7.21	10/19/93
	H	5	4	8	0	7	7	6	01/02/96	Dullien	435	7.9	05/12/94
	I	5	6	2	3	9	3	9	04/29/97	Garfield	128	733	06/07/95
	J	5	6	5	0	3	9	4	07/22/97	Terao <i>et al.</i>	514	14	11/04/93
	K	6	2	6	7	7	2	2	07/31/01	Anderson <i>et al.</i>	600	300	02/03/98
	L	6	3	9	4	9	5	2	05/28/02	Anderson <i>et al.</i>	600	300	04/20/98

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	M	0	1	6	2	2	9	8	08/30/01 (A2)	PCT				
	N	0	3	1	6	9	1	9	07/06/95	EP				
	O	0	6	4	2	6	6	7	01/10/01	EP				
	P	6	1	1	9	2	9	1	04/28/94	JP			X	
	Q	9	2	1	0	5	8	5	06/25/92	PCT				
	R	9	3	0	9	4	3	2	05/13/93	PCT				
	S	9	3	2	4	8	3	6	12/09/93	PCT				
	T	9	3	2	4	8	3	8	12/09/93	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
24727-801FSERIAL NO.
10/043,356LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
LaPointe *et al.*FILING DATE
June 11, 2002GROUP
2122

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	U	9	4	1	7	4	0	5	08/04/94	PCT				
	V	9	4	2	7	4	9	0	12/08/94	PCT				
	W	9	5	1	2	4	0	6	05/11/95	PCT				
	X	9	6	0	3	9	2	9	02/15/98	PCT				
	Y	9	6	2	6	2	7	3	08/29/96	PCT				
	Z	9	7	2	9	4	4	7	08/14/97	PCT				
	AA	9	7	4	5	7	4	4	12/04/97	PCT				
	AB	9	9	0	9	5	0	7	02/25/99	PCT				
	AC	9	9	3	9	2	9	8	08/05/99	PCT				

X - English Translation being provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AD	Ahner <i>et al.</i> , "Fetal fibronectin as a selection criterion for induction of term labor", <i>Am. J. Obstet. Gynecol.</i> , 173:1513-1517, 1995
AE	Allen <i>et al.</i> , "Help for high-risk pregnancies", San Jose Mercury News, February 7, 2003 edition
AF	Bailit <i>et al.</i> , "Reducing the caesarean delivery risk in elective inductions of labour: a decision analysis", <i>Pediatric and Perinatal Epidemiology</i> , 16:90-96, 2002
AG	Blanch <i>et al.</i> , "The presence of fetal fibronectin in the cervicovaginal secretions of women at term - Its role in the assessment of women before labor induction and in the investigation of the physiologic mechanisms of labor", <i>Am. J. Obstet. Gynecol.</i> , 174:262-266, 1996
AH	Breart <i>et al.</i> , "A comparative study of the efficiency of hydroxyprogesterone caproate and of chlormadinone acetate in the prevention of premature labor", <i>Int. J. Gynaecol. Obstet.</i> , 16:381-384, 1979
AI	Castellani <i>et al.</i> , "The fibronectin isoform containing the ED-B Oncofetal Domain: A Marker of Angiogenesis", <i>Int. J. Cancer</i> , 59:612-618, 1994

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24727-801F	SERIAL NO. 10/043,356
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT LaPointe <i>et al.</i>	
	FILING DATE June 11, 2002	GROUP 2122

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AJ	Citation 1: English translation and Japanese version of <u>Mitsubishi Electric Technical Report</u> , Vol. 68, No. 8, Special Edition on "Neural Network Application Technology", August 1994
AK	Citation 2: English Translation and Japanese version of <u>Personal Computer Statistical Analysis Handbook II Multivariate Analysis Edition</u> , Tanaka <i>et al.</i> , (Editors), November 1997
AL	Citation 3: English Translation of Japanese Patent No. 6-119291 (Cited at document D), published April 28, 1994, Kurokawa <i>et al.</i> , for "Water Supply Prediction Device"
AM	Citation 4: English Translation and Japanese version of <u>International Academic Society Article 1999-01322-004</u> , Bibliographic Item Printing, November 12, 2002
AN	Citation 5: English Translation and Japanese version of <u>International Academic Society Article 1999-00312-010</u> , Bibliographic Item Printing, November 12, 2002
AO	Creasy <i>et al.</i> , "Prevention of Preterm Birth", <i>Seminars in Perinatology</i> , 5(3):395-302, 1981
AP	Fuller, William E., "Management of Premature Labor", <i>Clinical Obstetrics and Gynecology</i> , 21(2):533-545, 1978
AQ	Garite <i>et al.</i> , "Fetal fibronectin: A new tool for the prediction of successful induction of labor", <i>Am. J. Obstet. Gynecol.</i> , 175:1516-1521, 1996
AR	Goldstein <i>et al.</i> , "A meta-analysis of randomized control trials of progestational agents in pregnancy", <i>British J. Obstet. Gynecol.</i> , 96:265-274, 1989
AS	Grady, Denise, "Hormone Cuts Risk of Premature Birth", <i>The New York Times</i> , February 7, 2003 Edition
AT	Gyetvai <i>et al.</i> , "Tocolytics for preterm labor: a systematic review", <i>Obstet. Gynecol.</i> , 94(5 Pt 2):869-877, 1999
AU	Halin <i>et al.</i> , "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature", <i>Nature Biotechnology</i> , 20:264-269, 2002
AV	Hartikainen-Sorri <i>et al.</i> , "Inefficacy of 17 α -Hydroxyprogesterone Caproate in the Prevention of Prematurity in Twin Pregnancy", <i>Obstet. Gynecol.</i> , 56(6):692-695, 1980
AW	Hauth <i>et al.</i> , "The effect of a 17 α -hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population", <i>Am. J. Obstet. Gynecol.</i> , 146:187-190, 1983

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24727-801F	SERIAL NO. 10/043,356
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT LaPointe <i>et al.</i>	
	FILING DATE June 11, 2002	GROUP 2122

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AX		Imai <i>et al.</i> , "Significance of fetal fibronectin and cytokine measurement in the cervicovaginal secretions of women at term in predicting term labor and post-term pregnancy", <i>European J. Obstet. Gynecol. Reprod. Biol.</i> , <u>97</u> :53-58, 2001
AY		Johnson <i>et al.</i> , "High-Risk Prematurity--Progestin Treatment and Steroid Studies", <i>Obstet. Gynecol.</i> , <u>54</u> (4):412-418, 1979
AZ		Johnson <i>et al.</i> , "Efficacy of 17 α -Hydroxyprogesterone aproate in the prevention of premature labor", <i>N. Eng. J. Med.</i> , <u>293</u> (14):675-680, 1975
BA		Kaczmarek <i>et al.</i> , "Distribution of Oncofetal Fibronectin Isoforms in Normal Hyperplastic and Neoplastic Human Breast Tissues", <i>Int. J. Cancer</i> , <u>58</u> :11-16, 1994
BB		Kahn <i>et al.</i> , "Preliminary Investigation of a Bayesian Network for Mammographic Diagnosis of Breast Cancer", <i>Proceedings of the 19th Annual Symposium on Computer Applications in Medical Care</i> , pp. 208-212 (1995)
BC		Kauppi <i>et al.</i> , "Suppression of threatened premature labor by administration of cortisol and 17 α -hydroxyprogesterone caproate: A comparison with ritodrine", <i>Am. J. Obstet. Gynecol.</i> , <u>138</u> :404-408, 1980
BD		Keirse <i>et al.</i> , "Progestogen administration in pregnancy may prevent preterm delivery", <i>Br. J. Obstet. Gynecol.</i> , <u>97</u> :149-154, 1990
BE		Kiss <i>et al.</i> , "Fetal fibronectin as a predictor of term labor: A literature review", <i>Acta Obstet. Gynecol. Scand.</i> , <u>79</u> :3-7, 2000
BF		Lockwood <i>et al.</i> , "Fetal Fibronectin in Cervical and Vaginal Secretions as a Predictor of Preterm Delivery", <i>New England J. of Medicine</i> , <u>325</u> (10):569-674, 1991
BG		Marty <i>et al.</i> , "Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes", <i>British J. Cancer</i> , <u>87</u> :106-112, 2002
BH		Reijnders <i>et al.</i> , "Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial", <i>Br. J. Obst. Gynaecol.</i> , <u>95</u> :462-468, 1988
BI		Rozenberg <i>et al.</i> , "Comparison of the Bishop score, ultrasonographically measured cervical length, and fetal fibronectin assay in predicting time until delivery and type of delivery at term", <i>Am. J. Obstet. Gynecol.</i> , <u>182</u> :108-113, 2002
BJ		Yemini <i>et al.</i> , "Prevention of premature labor by 17 α -hydroxyprogesterone caproate", <i>Am. J. Obstet. Gynecol.</i> , <u>151</u> :574-577, 1985

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

BEST AVAILABLE COPY

THE STAMP OF THE U.S. PATENT AND TRADEMARK OFFICE
AFFIXED HERETO WILL BE EVIDENCE OF RECEIPT OF THE
FOLLOWING (SENT VIA FIRST CLASS PRIORITY MAIL) ON
October 18, 2002

Client No.: 24727-801F

Enclosures: 1) Executed Declaration For Patent Application;
2) Transmittal Letter; 3) This return postcard

Applicant(s): Lapointe et al.
Serial No. 10/043,356 Filed: January 11, 2002
For: METHOD FOR SELECTING MEDICAL AND
BIOCHEMICAL DIAGNOSTIC TESTS USING NEURAL
NETWORK-RELATED APPLICATIONS

SLS:kcc

